Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III trial of prolonged-release naloxone for opioid-induced constipation
2017-000657-39Phase 3Completed
- Sponsor
- Develco Pharma
- Start
- May 2017
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of naloxone in opioid-induced constipation (OIC) (3 arms), sponsored by Develco Pharma. Primary endpoint: Proportion of overall complete spontaneous bowel movement responders. Started May 2017; status: completed.
02
Drugs
naloxone
03
Conditions
opioid-induced constipation (OIC)
Beyond the preview
Go deeper on 2017-000657-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-000657-39.